Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY (2022) Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Translational Medicine 20:135.
Summary: The authors describe how a conjugate of Saporin and ATF (Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer amino‐terminal fragment of urokinase) exerts antitumor effects by targeting Urokinase-type plasminogen activator receptor (uPAR).